Charles Fuchs, MD: Percentage of RAS Mutation Tests in Metastatic CRC

Pixatimod and nivolumab showed benefits for patients with microsatellite-stable metastatic colorectal cancer.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Encouraging results in melanoma have led experts to explore the gut microbiome in colorectal cancer.  The next hot topic in research may be the gut microbiome's role for the prevention, progression, and management of colorectal cancer.

In season 2, episode 2 of Targeted Talks, Cathy Eng, MD, speaks with Benjamin Weinberg, MD, about the gut microbiome, and how the presence of certain microbiota impact the onset and intensity of disease as well as the potential response to certain treatments.

Despite achieving the co-primary end points, the phase 3 PRESERVE trial of trilaciclib in patients with metastatic colorectal cancer will be terminated.

Results of a study of dabrefenib, trametinib, and spartalizumab showed efficacy for the combination of a BRAF inhibitor, a MEK inhibitor, and an anti–PD-1 agent in patients with BRAF V600-mutated colorectal cancer.